Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b investigator initiated trial of combination therapy of Metformin and Nivolumab in participants with advanced or recurrent solid cancer.

Trial Profile

Phase 1b investigator initiated trial of combination therapy of Metformin and Nivolumab in participants with advanced or recurrent solid cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Metformin (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, this study will enroll 9-18 patients in part 1 and 30 patient in part 2. enrollment is expected to be completed by 2019.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top